Change over period: —
NSE · SYNCOMF
SYNCOM FORM.
-15.7% from the 52-week high · +114.4% above the low
Syncom Formulation India Ltd. is a pharmaceutical company, which engages in the development, manufacture, and marketing of healthcare products. The company is headquartered in Indore, Madhya Pradesh and currently employs 799 full-time employees. The firm is engaged in the manufacturing and dealing in pharmaceutical drugs and formulations, and trading of commodities. The company is also engaged in the renting of properties. The company manufactures and markets a range of pharmaceutical formulations in various dosage forms, such as tablets, capsules, liquids orals, liquid vials and ampoule injections and dry powder injections, ophthalmic preparations, dry syrups and suspensions, ointments, creams, gel, ORS and jelly. The firm's domestic division product categories include Cratus Life Care, Cratus Evolve and Cratus Right Nutrition. Its products include Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Ciprofloxacin Tablets USP 750 mg, Cefazolin For Injection USP 1 gm, Cefotaxime For Injection USP 1 gm, Ceftriaxone for Injection USP 500 mg, Cefuroxime For Injection USP 750 mg and Gentamicin Injection BP 40 mg.
The short version. SYNCOM FORM. reported revenue of ₹142 crore for Sep 2026, up 16.4% from a year earlier. Net profit was ₹27 crore (up 58.8% year on year). Return on equity was 18.4% in Mar 2026. Promoter holding was 50.57% in Sep 2026, up 0.00 points over 8 quarters.
1 · The price
How has the stock traded?
SYNCOM FORM. trades 15.7% below its 52-week high and 114.4% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹142 cr.
Sep 2026 net profit of ₹27 cr.
5.2 pts higher than a year earlier.
Revenue compounded at 29.6% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 142 | 126 | 135 | 115 | 122 | 117 | 149 | 128 |
| Net profit | 27 | 25 | 25 | 19 | 17 | 16 | 18 | 13 |
| Net margin % | 18.8 | 19.8 | 18.6 | 16.4 | 13.6 | 13.5 | 11.9 | 10.2 |
| EPS (₹) | 0.28 | 0.26 | 0.27 | 0.2 | 0.18 | 0.17 | 0.19 | 0.14 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | 489 | 465 | 263 | 224 |
| Net profit | 76 | 49 | 25 | 20 |
| Net margin % | 15.6 | 10.6 | 9.6 | 8.9 |
| EPS (₹) | 0.81 | 0.53 | 0.27 | 0.21 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 18.4% in Mar 2026; debt to equity is 0.00.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 18.4 | 14.4 | 8.8 | 7.8 |
| Return on capital % | 23.8 | 18.8 | 12.9 | 11.2 |
| EBITDA margin % | 20.9 | 14.8 | 15.6 | 14.3 |
| Net margin % | 14.7 | 10.2 | 9.1 | 8.4 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 29.6% | — |
| Profit CAGR | 56.2% | — |
4 · The owners
Who holds it, and are they adding?
Unchanged over 8 quarters.
Up 2.09 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 50.57 | 50.57 | 50.57 | 50.57 | 50.57 | 50.57 | 50.57 | 50.57 | 0.0 |
| FII | 0.13 | 0.11 | 0.41 | 0.1 | 0.26 | 0.21 | 0.35 | 2.22 | +2.09 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 49.3 | 49.32 | 49.02 | 49.33 | 49.17 | 49.21 | 49.08 | 47.2 | -2.1 |
Mutual fund holdings · Oct 2026
2 schemes hold this stock
2 the month before.
- Motilal Oswal BSE Healthcare ETF0.06% of NAV
- Bandhan BSE Healthcare Index Fund0.06% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for SYNCOM FORM. are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about SYNCOM FORM.
What is the SYNCOM FORM. share price?
SYNCOM FORM. (SYNCOMF) last closed at ₹22.09, up 0.05% on the day. Its 52-week range is ₹10.30 to ₹26.18.
What is the market cap of SYNCOM FORM.?
SYNCOM FORM. has a market capitalisation of about ₹2,074 crore. Its price-to-earnings ratio is 21.3.
How are SYNCOM FORM.'s latest results?
SYNCOM FORM. reported revenue of ₹142 crore for Sep 2026, up 16.4% from a year earlier. Net profit was ₹27 crore (up 58.8% year on year). Return on equity was 18.4% in Mar 2026. Promoter holding was 50.57% in Sep 2026, up 0.00 points over 8 quarters.
Who owns SYNCOM FORM.?
As of Sep 2026, shareholding was: Promoter 50.57%, FII 2.22%, Public 47.2%.
How many mutual funds hold SYNCOM FORM.?
2 mutual fund schemes held SYNCOM FORM. in October 2026. That compares with 2 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 09 Sep 2022 · Final Dividend - Rs. 0.03
- 21 Sep 2017 · Dividend - Rs. 0.02
- 22 Sep 2016 · Dividend - Rs. 0.02
- 16 Sep 2015 · Dividend - Rs. 0.02
- 18 Sep 2014 · Dividend - Rs. 0.02
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.